Home > Rheumatology > EULAR 2022 > Tapering TNF blockers in axSpA and psoriatic arthritis: a successful approach

Tapering TNF blockers in axSpA and psoriatic arthritis: a successful approach

Presented By
Dr Celia Michielsens, Radboud Institute for Health Sciences,  the Netherlands
Conference
EULAR 2022
In both psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), a treat-to-target (T2T) TNF blocker tapering strategy showed to be non-inferior to a T2T strategy without tapering regarding the proportion of patients still in low disease activity at 12 months. The only disadvantage of this approach was an increase in the use of other medications, especially non-steroidal anti-inflammatory drugs (NSAIDs) in the tapering group. Although TNF blockers are safe and effective, high costs and a somewhat increased infection risk are long-term drawbacks. Therefore, tapering in patients that successfully achieved low disease activity or remission in PsA or axSpA might be a valuable approach. Dr Celia Michielsens (Sint Maartenskliniek and Radboud Institute for Health Sciences,  the Netherlands) and her team investigated whether a T2T strategy with tapering is non-inferior (with a pre-specified non-inferiority margin of 20%) compared with a T2T strategy without t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on